Betta Financial Statements From 2010 to 2024

Stocks . China . 
Stock . Betta Pharmaceuticals Co
300558 Stock   52.69  1.11  2.06%   
Betta Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Betta Pharmaceuticals Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Betta Pharmaceuticals financial statements helps investors assess Betta Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Betta Pharmaceuticals' valuation are summarized below:
Gross Profit
2.1 B
Profit Margin
0.1667
Market Capitalization
23 B
Enterprise Value Revenue
8.7139
Revenue
2.8 B
We have found seventy-nine available fundamental signals for Betta Pharmaceuticals Co, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Betta Pharmaceuticals Co prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Betta Pharmaceuticals Total Revenue

1.38 Billion

Check Betta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Betta Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 32.1 M, Selling General Administrative of 632.6 M or Total Revenue of 1.4 B, as well as many indicators such as . Betta financial statements analysis is a perfect complement when working with Betta Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Betta Pharmaceuticals Technical models . Check out the analysis of Betta Pharmaceuticals Correlation against competitors.

Betta Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.6 B9.1 B3.6 B
Slightly volatile
Other Current Liabilities3.9 M4.1 M62 M
Pretty Stable
Total Current Liabilities1.9 B1.8 B659.9 M
Slightly volatile
Total Stockholder Equity5.5 B5.3 B2.3 B
Slightly volatile
Other Liabilities833.7 M794 M323.4 M
Slightly volatile
Accounts Payable840.1 M800.1 M214.2 M
Slightly volatile
Cash466.3 M752 M399.8 M
Slightly volatile
Other Assets1.6 B1.5 B680.7 M
Slightly volatile
Long Term Debt1.9 B1.8 B501.1 M
Slightly volatile
Net Receivables300.7 M286.4 M111.8 M
Slightly volatile
Short Term Investments589.4 K620.4 K151.8 M
Very volatile
Inventory343.9 M327.5 M141.9 M
Slightly volatile
Other Current Assets147.4 M140.4 M54.1 M
Slightly volatile
Total Liabilities4 B3.8 B1.2 B
Slightly volatile
Intangible Assets3.3 B3.2 B1.2 B
Slightly volatile
Common Stock341.2 M477.7 M313.2 M
Slightly volatile
Property Plant Equipment1.6 B1.5 B691.3 M
Slightly volatile
Retained Earnings1.2 B2.3 B1 B
Slightly volatile
Net Tangible Assets2 B3.4 B1.6 B
Slightly volatile
Deferred Long Term Liabilities1.5 B1.4 B567.5 M
Slightly volatile
Long Term Investments102.3 M77.3 M112.4 M
Slightly volatile
Short and Long Term Debt297.1 M300.3 M197.4 M
Slightly volatile
Total Current Assets1.3 B1.5 B972.1 M
Slightly volatile
Short Term Debt258.4 M417.7 M199.2 M
Slightly volatile
Non Current Assets Total4.3 B7.6 B2.7 B
Slightly volatile
Non Currrent Assets Other15.7 M16.5 M409.5 M
Slightly volatile
Non Current Liabilities Total2.1 B2 B544.1 M
Slightly volatile
Net Debt1.4 B1.4 B324.2 M
Slightly volatile
Good Will332.5 M372.2 M406.3 M
Slightly volatile
Common Stock Shares Outstanding450.6 M418.5 M408.3 M
Slightly volatile
Net Invested Capital4.8 B7.4 B3.4 B
Slightly volatile
Non Current Liabilities Other242 M322 M184.3 M
Slightly volatile
Capital Stock452.2 M418.5 M408.4 M
Slightly volatile
Property Plant And Equipment Net1.7 B2.6 B1.1 B
Slightly volatile
Property Plant And Equipment Gross2 B3.1 B1.3 B
Slightly volatile
Capital Lease Obligations7.6 M8.2 M6.2 M
Slightly volatile

Betta Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative632.6 M987 M543.9 M
Slightly volatile
Total Revenue1.4 B2.5 B1.2 B
Slightly volatile
Operating Income285.1 M332.1 M243.7 M
Slightly volatile
Research Development672.1 M640.1 M290.5 M
Slightly volatile
Cost Of Revenue424.7 M404.5 M118.1 M
Slightly volatile
Income Before Tax311.8 M322.1 M267.6 M
Slightly volatile
Minority Interest9.1 M14.4 M7.5 M
Slightly volatile
Income Tax Expense11.3 M11.9 M28.5 M
Very volatile
Gross Profit1.6 B2.1 B1.3 B
Slightly volatile
Other Operating Expenses12.2 M13.7 M16.3 M
Slightly volatile
Net Income From Continuing Ops248 M333.6 M317 M
Pretty Stable
EBIT260.6 M313.9 M333.1 M
Pretty Stable
Total Operating Expenses1.4 B2.1 B1.1 B
Slightly volatile
Total Other Income Expense Net827 K870.6 K25.5 M
Slightly volatile
Net Income Applicable To Common Shares370.7 M440.5 M352 M
Pretty Stable
Net Income348.6 M348 M328.5 M
Very volatile
Interest Income7.7 M10.2 M5 M
Slightly volatile
EBITDA569.2 M617.6 M454.9 M
Slightly volatile
Reconciled Depreciation188.1 M303.5 M124.1 M
Slightly volatile

Betta Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividends Paid72.1 M110.3 M62 M
Slightly volatile
Capital Expenditures1.2 B1.1 B485.6 M
Slightly volatile
Total Cash From Operating Activities959.9 M914.2 M397.2 M
Slightly volatile
Other Cashflows From Investing Activities767 M730.5 M314.3 M
Slightly volatile
Depreciation318.7 M303.5 M109.5 M
Slightly volatile
Net Income348.6 M348 M328.5 M
Very volatile
Change To Liabilities216 M205.8 M91.4 M
Slightly volatile
End Period Cash Flow662 M752 M426.7 M
Slightly volatile
Begin Period Cash Flow638.4 M731.3 M385.3 M
Slightly volatile
Other Non Cash Items58.6 M48.2 M31.7 M
Slightly volatile

About Betta Pharmaceuticals Financial Statements

Betta Pharmaceuticals stakeholders use historical fundamental indicators, such as Betta Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Betta Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Betta Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Betta Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Betta Pharmaceuticals Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue2.5 B1.4 B
Cost Of Revenue404.5 M424.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Other Information on Investing in Betta Stock

Betta Pharmaceuticals financial ratios help investors to determine whether Betta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Betta with respect to the benefits of owning Betta Pharmaceuticals security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY